MTW1 Antibody

What is the MTW-1 antibody and what target does it recognize?

MTW-1 is a rat recombinant monoclonal antibody that specifically recognizes TWEAK (Tumor necrosis factor ligand superfamily member 12, also known as TNFSF12). It binds to mouse TWEAK with high specificity and was raised using an immunogen corresponding to recombinant protein within Mouse Tnfsf12 . The antibody was originally developed by immunizing SD rats with CD8-mTWEAK, a fusion of the human CD8alpha extracellular region to murine TWEAK .

What are the known functional properties of the TWEAK target?

TWEAK (TNF-related weak inducer of apoptosis) exhibits multiple biological functions in experimental systems. It binds to FN14 and possibly also to TNRFSF12/APO3 receptors. As its name suggests, it is a weak inducer of apoptosis in certain cell types. TWEAK mediates NF-kappa-B activation, promotes angiogenesis, and stimulates the proliferation of endothelial cells. Additionally, it plays a role in inflammatory processes by inducing cytokine production, including promotion of IL8 secretion .

What applications has MTW-1 antibody been validated for?

The MTW-1 antibody has been validated for several research applications including:

• Immunocytochemistry/Immunofluorescence (ICC/IF) with mouse samples

• Flow cytometry applications with mouse samples

• Neutralization assays

How should I optimize immunofluorescence protocols when using MTW-1 antibody?

For optimal immunofluorescence results with MTW-1 antibody, follow this validated protocol: Fix cells with paraformaldehyde and immobilize on appropriate cover-slips (such as Shi-fixTM). Use MTW-1 antibody at a concentration of 10 μg/ml followed by an appropriate secondary antibody such as Alexa Fluor® 488 at 2 μg/ml. Include a nuclear counterstain such as DAPI for reference. When working with splenocytes or similar mouse samples, expect to observe membrane staining in a subset of cells rather than uniform staining across all cells . This heterogeneous staining pattern is consistent with the selective expression of TWEAK across different immune cell populations.

What controls should I include when performing flow cytometry with MTW-1 antibody?

For rigorous flow cytometry experiments using MTW-1 antibody, include the following controls:

• Isotype control (rat IgG1 κ) at the same concentration as MTW-1 to assess non-specific binding

• Unstained cells to establish autofluorescence baseline

• FMO (Fluorescence Minus One) controls if using multiple markers

• Known TWEAK-positive and TWEAK-negative cell populations for reference

The antibody has been purified using Protein A and is supplied at a concentration of 1 mg/mL in PBS . Titrate the antibody in preliminary experiments to determine optimal concentration for your specific cell types.

What storage conditions are recommended to maintain MTW-1 antibody activity?

To maintain optimal MTW-1 antibody activity, store at 4°C for short-term use (up to 2 weeks). For long-term storage, aliquot the antibody and store at -20°C. Avoid repeated freeze-thaw cycles as these can degrade antibody quality and compromise experimental results . This recommendation aligns with general best practices for monoclonal antibody storage to prevent degradation and maintain consistent performance across experiments.

How can I assess the neutralizing capacity of MTW-1 in TWEAK-mediated cellular responses?

To evaluate the neutralizing capacity of MTW-1 in TWEAK-mediated cellular responses, design experiments that measure specific downstream effects of TWEAK signaling:

• NF-κB Activation Assay: Utilize reporter cell lines expressing an NF-κB responsive element driving luciferase expression. Pre-incubate recombinant TWEAK with varying concentrations of MTW-1 antibody before adding to cells, then measure reduction in luciferase signal compared to non-neutralized controls.

• Angiogenesis Inhibition: Employ endothelial tube formation assays or endothelial cell proliferation assays in the presence of TWEAK with or without MTW-1 pre-treatment. Quantify reduction in tubule formation or proliferation rate to determine neutralization efficacy.

• Cytokine Secretion: Measure the inhibition of TWEAK-induced IL-8 secretion in appropriate cell lines using ELISA after pre-incubation of TWEAK with MTW-1 .

When designing these experiments, include appropriate dose-response curves to determine the IC50 of the antibody for each biological readout.

How does MTW-1 compare to other anti-TWEAK antibodies in terms of epitope specificity?

While the precise epitope recognized by MTW-1 has not been fully characterized in the provided sources, its binding specificity can be compared to other anti-TWEAK antibodies through competitive binding assays. Similar to approaches used for other target proteins (such as the anti-MUC1 antibody 139H2), epitope mapping of MTW-1 could be performed using techniques like:

• Peptide array analysis with overlapping TWEAK peptide sequences

• Hydrogen-deuterium exchange mass spectrometry to identify protected regions upon binding

• X-ray crystallography of the antibody-antigen complex to definitively resolve the binding interface

Understanding the exact epitope would provide insights into whether MTW-1 might interfere with TWEAK's interaction with its receptors, explaining its neutralizing capabilities.

What is the role of MTW-1 in studying TWEAK-mediated inflammatory pathways?

MTW-1 serves as a valuable tool for dissecting TWEAK-mediated inflammatory pathways in mouse models. TWEAK has been implicated in the induction of inflammatory cytokines and promotes IL8 secretion . Researchers can use MTW-1 to:

• Neutralize TWEAK activity in ex vivo tissue cultures to assess baseline and stimulated cytokine production

• Block TWEAK-FN14 interactions in mouse models of inflammatory diseases

• Identify TWEAK-expressing cell populations in inflammatory microenvironments using flow cytometry or immunohistochemistry

The ability to neutralize TWEAK function makes MTW-1 particularly useful for mechanistic studies seeking to distinguish TWEAK-dependent from TWEAK-independent inflammatory processes.

How can I address weak or absent staining when using MTW-1 for immunofluorescence?

When encountering weak or absent staining with MTW-1 in immunofluorescence applications, consider these optimization strategies:

• Fixation Method: Ensure cells are properly fixed with paraformaldehyde rather than alternative fixatives that might mask the epitope.

• Antibody Concentration: Increase the concentration of MTW-1 from the recommended 10 μg/ml up to 20 μg/ml.

• Permeabilization: If targeting intracellular TWEAK pools, optimize permeabilization conditions carefully.

• Signal Amplification: Consider using biotin-streptavidin systems or tyramide signal amplification if the target is expressed at low levels.

• Sample Selection: Recall that TWEAK shows heterogeneous expression, with membrane staining visible only in a subset of cells . Ensure your samples contain TWEAK-expressing cell populations.

What considerations are important for long-term stability studies of MTW-1 antibody?

For long-term stability assessment of MTW-1 antibody, implement a systematic approach similar to developability assessment studies used for therapeutic antibodies :

• Conduct short-term stability studies at multiple temperatures (2-8°C, 25°C, and 40°C) to establish degradation kinetics

• Perform freeze-thaw cycle testing (typically 3-5 cycles) to assess resilience to standard laboratory handling

• Evaluate limited forced degradation studies (pH extremes, oxidation) to identify vulnerable modifications

• Monitor functional activity (binding, neutralization) at each time point, not just physical stability

• Use orthogonal analytical methods (SEC, CE-SDS, mass spectrometry) to detect various degradation pathways

This approach provides comprehensive data on storage conditions and handling practices that maintain MTW-1 functionality over time.

How should I validate lot-to-lot consistency when working with MTW-1 antibody across extended research projects?

To ensure experimental reproducibility with different lots of MTW-1 antibody over extended research periods:

• Establish a reference standard from a well-characterized lot and store multiple aliquots at -80°C

• Develop quantitative assays to compare new lots against the reference:

  • Flow cytometry titration on a consistent positive control cell line

  • Quantitative ELISA against recombinant TWEAK

  • Side-by-side neutralization potency assessment

• Create detailed specifications with acceptable variation limits for critical parameters

• Document lot-specific optimal concentrations for each application

• If significant differences are observed, consider normalizing data based on relative potency

This systematic approach for antibody validation mirrors practices used during therapeutic antibody development and ensures reliable results throughout long-term research projects.

How can MTW-1 antibody be utilized in studying TWEAK's role in cancer biology?

MTW-1 antibody offers valuable opportunities for investigating TWEAK's complex role in cancer biology:

• Tumor Microenvironment Analysis: Use MTW-1 for immunofluorescence or flow cytometry to map TWEAK expression patterns within tumor and surrounding tissue, potentially identifying correlations with infiltrating immune cells.

• Angiogenesis Studies: Since TWEAK promotes angiogenesis and endothelial cell proliferation , MTW-1 can be employed in neutralization experiments to assess TWEAK's contribution to tumor vascularization in mouse models.

• NF-κB Signaling in Cancer Cells: Use MTW-1 to block TWEAK-mediated NF-κB activation in cancer cells to study downstream effects on proliferation, migration, and therapy resistance.

Similar to approaches used with other target-specific antibodies like 139H2 , researchers can leverage MTW-1 to develop new insights into TWEAK's role in carcinogenesis and potential as a therapeutic target.

What methodological approaches can enhance the specificity of MTW-1 in complex tissue samples?

To maximize specificity when using MTW-1 in complex tissue samples:

• Multiplex Immunofluorescence: Combine MTW-1 with antibodies against known TWEAK-expressing cell markers to confirm signal specificity.

• TWEAK Knockout Controls: Include TWEAK-knockout tissues or cells as negative controls, similar to the validation approach described for MUC1 knockout cells with the 139H2 antibody .

• Absorption Controls: Pre-incubate MTW-1 with recombinant TWEAK protein before staining to demonstrate signal specificity through signal abolishment.

• Orthogonal Detection Methods: Confirm MTW-1 staining patterns using alternative detection methods such as in situ hybridization for TWEAK mRNA.

These approaches build upon established validation principles for monoclonal antibodies in complex biological systems.